Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.

NCT05201079 is registered in ClinicalTrials.gov with Mikrobiomik Healthcare Company S.L. as lead sponsor.

NCT NCT05201079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05201079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.
Lead sponsor
Mikrobiomik Healthcare Company S.L.
Phase
Phase 3
Overall status
Completed
Start date
October 29, 2021
Completion date
November 15, 2023
Enrollment
93 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

primary clostridium difficile infection, recurrent clostridium difficile infection